Details
Stereochemistry | ACHIRAL |
Molecular Formula | Fe.S |
Molecular Weight | 87.91 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[S--].[Fe++]
InChI
InChIKey=GNVXPFBEZCSHQZ-UHFFFAOYSA-N
InChI=1S/Fe.S/q+2;-2
Molecular Formula | HS |
Molecular Weight | 33.073 |
Charge | -1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | Fe |
Molecular Weight | 55.845 |
Charge | 2 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/14116934DOI: 10.1021/ja00949a016 Retrived from http://pubs.acs.org/doi/abs/10.1021/ja00949a016http://www.foodchemadditives.com/products/Ferrous-Lactatehttps://www.drugs.com/inactive/ferrous-oxide-389.htmlhttps://www.ncbi.nlm.nih.gov/pubmed/16694502http://nj.gov/health/eoh/rtkweb/documents/fs/0928.pdfhttp://www.druglead.com/cds/ferrous-iodide.htmlhttp://www.drugfuture.com/chemdata/ferroglycine-sulfate.htmlCurator's Comment: description was created based on several sources, including
http://www.minapharm.com/Public/ProductDetails.aspx?ProductCode=FERRO_SANO&langParam=en
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14116934DOI: 10.1021/ja00949a016 Retrived from http://pubs.acs.org/doi/abs/10.1021/ja00949a016http://www.foodchemadditives.com/products/Ferrous-Lactatehttps://www.drugs.com/inactive/ferrous-oxide-389.htmlhttps://www.ncbi.nlm.nih.gov/pubmed/16694502http://nj.gov/health/eoh/rtkweb/documents/fs/0928.pdfhttp://www.druglead.com/cds/ferrous-iodide.htmlhttp://www.drugfuture.com/chemdata/ferroglycine-sulfate.html
Curator's Comment: description was created based on several sources, including
http://www.minapharm.com/Public/ProductDetails.aspx?ProductCode=FERRO_SANO&langParam=en
Ferrous glycine sulfate (Ferro Sanol Duodenal®) is a chelate of ferrous sulfate and glycine. It is used for treatment of moderate to severe iron deficiency anemia, particularly during pregnancy and lactation, for children, persons following low-iron diets and cases of acute or chronic blood loss.
Originator
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | Unknown Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
|||
Primary | Ferro Sanol Duodenal Approved UseFerro Sanol is an iron substitute in case of latent or manifest iron deficiency with and without development of anaemia. |
|||
PubMed
Title | Date | PubMed |
---|---|---|
FERROUS IODIDE AS A SUBSTITUTE FOR VITAMIN A IN RATS. | 1932 Jul 1 |
|
FERROUS IODIDE AND LINOLEIC ACID IN VITAMIN A DEFICIENCY. A REPLY TO CERTAIN CRITICISMS. | 1932 Nov 11 |
|
THE ADMINISTRATION OF FERROUS IODIDE AND LINOLEIC ACID TO RATS DEPRIVED OF VITAMIN A. | 1932 Sep 30 |
|
THE USE OF FERROUS GLUCONATE IN THE TREATMENT OF HYPOCHROMIC ANEMIA. | 1937 Jul |
|
[Ferrous lactate as an oral iron preparation for therapeutic use]. | 1954 Nov 27 |
|
Clinical appraisal of drugs with special reference to a new chelate hematinic. | 1957 Jul 11 |
|
[FERROUS ASPARTATE IN THERAPY]. | 1964 Jan 1 |
|
[Historical notes on the therapy of depression]. | 1986 Nov 22 |
|
Determination of water in ferrous lactate by near infrared reflectance spectroscopy with a fibre-optic probe. | 1997 Oct |
|
Decreased treatment failure rates following duodenal release ferrous glycine sulfate in iron deficiency anemia associated with autoimmune gastritis and Helicobacter pylori gastritis. | 2007 |
|
Reversal of multidrug resistance by magnetic Fe3O4 nanoparticle copolymerizating daunorubicin and 5-bromotetrandrine in xenograft nude-mice. | 2009 |
|
Bioleaching of heavy metals from sewage sludge by indigenous iron-oxidizing microorganisms using ammonium ferrous sulfate and ferrous sulfate as energy sources: a comparative study. | 2009 Nov 15 |
|
The effect of iron treatment on adhesion molecules in patients with iron deficiency anemia. | 2010 Dec |
|
Endothelial dysfunction and inflammation induced by iron oxide nanoparticle exposure: Risk factors for early atherosclerosis. | 2011 Jun 10 |
|
Tolerability of different oral iron supplements: a systematic review. | 2013 Apr |
|
Effect of abomasal ferrous lactate infusion on phosphorus absorption in lactating dairy cows. | 2013 Jul |
|
A practical and successful desensitization protocol for immediate hypersensitivity reactions to iron salts. | 2014 |
|
Synthesis of phosphabenzenes by an iron-catalyzed [2+2+2] cycloaddition reaction of diynes with phosphaalkynes. | 2015 Jun 22 |
|
Reactivity enhancement of iron sulfide nanoparticles stabilized by sodium alginate: Taking Cr (VI) removal as an example. | 2017 Jul 5 |
|
Atomic Layer Deposition of Iron Sulfide and Its Application as a Catalyst in the Hydrogenation of Azobenzenes. | 2017 Mar 13 |
|
Continuous sulfidogenic wastewater treatment with iron sulfide sludge oxidation and recycle. | 2017 May 1 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/ppa/ferrous-salts.html
Unknown
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 17 03:22:58 UTC 2022
by
admin
on
Sat Dec 17 03:22:58 UTC 2022
|
Record UNII |
TH5J4TUX6S
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
215-268-6
Created by
admin on Sat Dec 17 03:22:58 UTC 2022 , Edited by admin on Sat Dec 17 03:22:58 UTC 2022
|
PRIMARY | |||
|
DTXSID5061665
Created by
admin on Sat Dec 17 03:22:58 UTC 2022 , Edited by admin on Sat Dec 17 03:22:58 UTC 2022
|
PRIMARY | |||
|
C022597
Created by
admin on Sat Dec 17 03:22:58 UTC 2022 , Edited by admin on Sat Dec 17 03:22:58 UTC 2022
|
PRIMARY | |||
|
SUB23221
Created by
admin on Sat Dec 17 03:22:58 UTC 2022 , Edited by admin on Sat Dec 17 03:22:58 UTC 2022
|
PRIMARY | |||
|
IRON(II) SULFIDE
Created by
admin on Sat Dec 17 03:22:58 UTC 2022 , Edited by admin on Sat Dec 17 03:22:58 UTC 2022
|
PRIMARY | |||
|
1317-37-9
Created by
admin on Sat Dec 17 03:22:58 UTC 2022 , Edited by admin on Sat Dec 17 03:22:58 UTC 2022
|
PRIMARY | |||
|
75897
Created by
admin on Sat Dec 17 03:22:58 UTC 2022 , Edited by admin on Sat Dec 17 03:22:58 UTC 2022
|
PRIMARY | |||
|
5803
Created by
admin on Sat Dec 17 03:22:58 UTC 2022 , Edited by admin on Sat Dec 17 03:22:58 UTC 2022
|
PRIMARY | |||
|
TH5J4TUX6S
Created by
admin on Sat Dec 17 03:22:58 UTC 2022 , Edited by admin on Sat Dec 17 03:22:58 UTC 2022
|
PRIMARY | |||
|
10290742
Created by
admin on Sat Dec 17 03:22:58 UTC 2022 , Edited by admin on Sat Dec 17 03:22:58 UTC 2022
|
PRIMARY | |||
|
M5355
Created by
admin on Sat Dec 17 03:22:58 UTC 2022 , Edited by admin on Sat Dec 17 03:22:58 UTC 2022
|
PRIMARY | Merck Index | ||
|
TH5J4TUX6S
Created by
admin on Sat Dec 17 03:22:58 UTC 2022 , Edited by admin on Sat Dec 17 03:22:58 UTC 2022
|
PRIMARY | |||
|
1724430
Created by
admin on Sat Dec 17 03:22:58 UTC 2022 , Edited by admin on Sat Dec 17 03:22:58 UTC 2022
|
PRIMARY | RxNorm |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
PARENT -> SALT/SOLVATE |